lunes, 23 de mayo de 2016

BMC Hematology | Home page

BMC Hematology | Home page

Biomed Central logo


We are excited to share with you some recent highlights from the open access journal BMC Hematology and invite you to submit your next manuscript to us.

Journal Scope
BMC Hematology is an open access, peer-reviewed journal that considers articles on basic, experimental and clinical research related to hematology. The journal welcomes submissions on non-malignant and malignant hematological diseases, hemostasis and thrombosis, hematopoiesis, stem cells and transplantation.

About the BMC Series – Open, Inclusive and Trusted
Serving the scientific community for over 15 years, the BMC seriesincludes 63 subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. Submit your next manuscript to one of our BMC-series journals and we will help you every step of the way-from pre-submission inquiries, quick publication upon acceptance to maximum post-publication visibility aimed at accelerating discovery of your research.

Reasons to Publish with Us
Growing international readership
Global visibility for your research
Rapid publication on acceptance

Article e-alerts
Icon Keep up to date with the journal’s leading-edge research bysigning up to receive article alerts.

Best wishes,

The BioMed Central Team

    The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma

    Sarah Brown, Samantha Hinsley, Mónica Ballesteros, Sue Bourne, Paul McGarry, Debbie Sherratt, Louise Flanagan, Walter Gregory, Jamie Cavenagh, Roger Owen, Cathy Williams, Martin Kaiser, Eric Low and Kwee Yong
    Published on: 17 May 2016

    Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

    Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Regina Garcia, Maria Teresa Voso, Stephen R. Larsen, David Valcarcel, Lewis R. Silverman, Barry Skikne and Valeria Santini
    Published on: 3 May 2016

BMC Series blog

No hay comentarios:

Publicar un comentario